Product/Regulation
BioMarin and Ascendis settle Yuviwel patent cases on a 20% U.S. royalty
Binding term sheet Aug. 30: 20% of U.S. net sales and 18% in the EU, Brazil, and South Korea until May 2030. A settlement Agreement is supposed to replace the sheet by Sept. 24, 2026; if not, the sheet stays binding.
